

Luis de la Cruz-Merino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4948990/publications.pdf>

Version: 2024-02-01

134
papers

6,522
citations

201674

27
h-index

71685

76
g-index

142
all docs

142
docs citations

142
times ranked

8641
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). <i>European Journal of Cancer</i> , 2022, 161, 26-37.	2.8	11
2	Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy. <i>Biomedicines</i> , 2022, 10, 284.	3.2	2
3	Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics. <i>Cancers</i> , 2022, 14, 1469.	3.7	6
4	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 821-833.	1.3	8
5	The complexity of cancer immunotherapy illustrated through skin tumors. <i>International Journal of Biological Markers</i> , 2022, 37, 113-122.	1.8	0
6	Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. <i>Clinical Cancer Research</i> , 2022, 28, 3658-3668.	7.0	5
7	Desarrollo de un protocolo de monitorización de fuga en perfusión de miembro aislado con gammacimara portatil. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 4-11.	0.0	0
8	Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). <i>Journal of Clinical Oncology</i> , 2021, 39, 586-598.	1.6	117
9	Abstract OT-13-06: Solti-1503 PROMETEO: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer. <i>Cancer Research</i> , 2021, 81, OT-13-06-OT-13-06.	0.9	2
10	SEOM clinical guideline for the management of cutaneous melanoma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 948-960.	2.4	22
11	Metabolic Classification and Intervention Opportunities for Tumor Energy Dysfunction. <i>Metabolites</i> , 2021, 11, 264.	2.9	7
12	Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1001-1001.	1.6	32
13	Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAF ^{V600} mutation-positive advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9523-9523.	1.6	0
14	94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study. <i>Annals of Oncology</i> , 2021, 32, S63.	1.2	1
15	Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9504-9504.	1.6	23
16	5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF ^{V600} Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021, 27, 5225-5235.	7.0	82
17	Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. , 2021, 9, e002323.		26
18	Leptin, Both Bad and Good Actor in Cancer. <i>Biomolecules</i> , 2021, 11, 913.	4.0	31

#	ARTICLE	IF	CITATIONS
19	Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer. <i>Scientific Reports</i> , 2021, 11, 14426.	3.3	17
20	Immunometabolism Modulation in Therapy. <i>Biomedicines</i> , 2021, 9, 798.	3.2	5
21	Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. <i>Annals of Oncology</i> , 2021, 32, 1015-1024.	1.2	144
22	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
23	Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial. <i>Cancers</i> , 2021, 13, 4622.	3.7	6
24	Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19. <i>Viral Immunology</i> , 2021, 34, 639-645.	1.3	13
25	Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. <i>Cancers</i> , 2021, 13, 5432.	3.7	4
26	Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature. <i>Cancers</i> , 2021, 13, 5485.	3.7	4
27	Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 801410.	4.8	6
28	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 514-524.	27.0	482
29	LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2 endocrine sensitive advanced breast cancer (ABC). <i>Annals of Oncology</i> , 2020, 31, S1151.	1.2	3
30	GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID 19 Pandemic in Spain. <i>Oncologist</i> , 2020, 25, e1339-e1345.	3.7	14
31	Adjuvant nivolumab versus ipilimumab in resected stage IIIB and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1465-1477.	10.7	330
32	14P Evolution of cytotoxic and regulatory T cells in blood and in tissue after neoadjuvant treatment in breast carcinoma. <i>Annals of Oncology</i> , 2020, 31, S21-S22.	1.2	0
33	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. <i>Future Oncology</i> , 2020, 16, 1801-1813.	2.4	8
34	Integrating the Tumor Microenvironment into Cancer Therapy. <i>Cancers</i> , 2020, 12, 1677.	3.7	24
35	Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice. <i>Clinical and Translational Oncology</i> , 2020, 22, 1778-1785.	2.4	10
36	Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer. <i>Medicine (United States)</i> , 2020, 99, e18298.	1.0	8

#	ARTICLE	IF	CITATIONS
37	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 213-222.	2.4	14
38	Abstract OT1-01-01: SOLTI-1503 PROMETEO: Combination of talimogene laherparepvec (T-VEC) with atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy. <i>Cancer Research</i> , 2020, 80, OT1-01-01-OT1-01-01.	0.9	4
39	New horizons in breast cancer: the promise of immunotherapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 117-125.	2.4	21
40	Obesity and Breast Cancer: Role of Leptin. <i>Frontiers in Oncology</i> , 2019, 9, 596.	2.8	175
41	Development and validation of a sexual relations satisfaction scale in patients with breast cancer "SEXSAT-Q". <i>Health and Quality of Life Outcomes</i> , 2019, 17, 143.	2.4	4
42	The tumour microenvironment as an integrated framework to understand cancer biology. <i>Cancer Letters</i> , 2019, 461, 112-122.	7.2	57
43	Interim results from ComPLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy) <i>TJ ETQq1 1</i> 0.784314 rgBT /Overall 2019, 30, v119-v120.	1.2	0
44	Evolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy. <i>Annals of Oncology</i> , 2019, 30, v515-v516.	1.2	1
45	Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2 ⁺) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). <i>Annals of Oncology</i> , 2019, 30, v856-v857.	1.2	34
46	LENALIDOMIDE PLUS R-GDP (R2-GDP) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. PRELIMINARY RESULTS OF THE R2-GDP-GOTEL TRIAL. <i>Hematological Oncology</i> , 2019, 37, 258-259.	1.7	1
47	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
48	Myeloid derived-suppressor cells in healthy women and in advanced breast cancer patients. <i>Annals of Oncology</i> , 2019, 30, iii19.	1.2	1
49	Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group. <i>Hematological Oncology</i> , 2019, 37, 143-150.	1.7	9
50	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. <i>PLoS ONE</i> , 2019, 14, e0212813.	2.5	31
51	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 1375-1383.	3.7	22
52	Pneumonitis Related to Melanoma Immunotherapy. <i>Clinical Nuclear Medicine</i> , 2019, 44, e392-e393.	1.3	7
53	SEOM clinical guidelines in advanced and recurrent breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 31-45.	2.4	14
54	Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2019, 60, 1576-1579.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Abstract PD2-05: Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study. <i>Cancer Research</i> , 2019, 79, PD2-05-PD2-05.	0.9	15
56	Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2543-2543.	1.6	1
57	Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy. <i>Translational Cancer Research</i> , 2019, 8, 59-65.	1.0	11
58	Abstract P6-18-17: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: ComplEEment-1 trial, preliminary results from Spanish population. , 2019, , .		0
59	Results from a Phase II Trial of Pembrolizumab (P) Plus Gemcitabine (GEM) in patients (PTS) with HER2-Negative Advanced Breast Cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study. <i>Annals of Oncology</i> , 2019, 30, xi38-xi39.	1.2	0
60	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutationâ€“positive melanoma. <i>British Journal of Cancer</i> , 2018, 118, 777-784.	6.4	19
61	SEOM clinical guideline for the management of malignant melanoma (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 69-74.	2.4	16
62	Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962). <i>Annals of Oncology</i> , 2018, 29, viii443.	1.2	22
63	Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast. <i>Annals of Oncology</i> , 2018, 29, x32.	1.2	2
64	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018, 36, 2465-2472.	1.6	704
65	Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses. <i>Annals of Oncology</i> , 2018, 29, viii113-viii114.	1.2	2
66	Ribociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3. <i>Annals of Oncology</i> , 2018, 29, viii107.	1.2	0
67	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. <i>European Journal of Cancer</i> , 2018, 104, 201-209.	2.8	37
68	MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 519-526.	0.5	14
69	2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. <i>Clinical and Translational Oncology</i> , 2018, 20, 1361-1372.	2.4	35
70	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.		111
71	nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. <i>Annals of Oncology</i> , 2018, 29, 1763-1770.	1.2	94
72	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. <i>Blood</i> , 2018, 132, 2892-2892.	1.4	4

#	ARTICLE	IF	CITATIONS
73	90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.. Journal of Clinical Oncology, 2018, 36, 7550-7550.	1.6	1
74	Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF ^{V600} mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.. Journal of Clinical Oncology, 2018, 36, 9522-9522.	1.6	24
75	Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22).. Journal of Clinical Oncology, 2018, 36, 9546-9546.	1.6	5
76	Breast Cancer Immunology and Immunotherapy. International Review of Cell and Molecular Biology, 2017, 331, 1-53.	3.2	47
77	More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. European Journal of Cancer, 2017, 75, 313-322.	2.8	32
78	Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group. Cancer, 2017, 123, 3709-3716.	4.1	23
79	Follicular lymphoma: clinical and molecular characteristics of histologic transformation. Annals of Oncology, 2017, 28, v358-v359.	1.2	0
80	Nuevos avances de tratamiento inmunobiológico en el melanoma avanzado. Actas Dermo-sifilográficas, 2017, 108, 721-728.	0.4	0
81	Advances in the Immunobiological Therapies for Advanced Melanoma. Actas Dermo-sifilográficas, 2017, 108, 721-728.	0.4	0
82	Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of Translational Medicine, 2017, 15, 146.	4.4	36
83	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. Journal of Clinical Oncology, 2017, 35, 7537-7537.	1.6	2
84	Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.. Journal of Clinical Oncology, 2017, 35, 9533-9533.	1.6	13
85	A phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER+/HER2- advanced or metastatic breast cancer (mBC) that has progressed during or after aromatase inhibitor (AI) therapy.. Journal of Clinical Oncology, 2017, 35, TPS1118-TPS1118.	1.6	0
86	Treatment patterns of adjuvant interferon- β for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma "Prima" study. Melanoma Research, 2016, 26, 278-283.	1.2	8
87	Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02. Annals of Oncology, 2016, 27, vi377.	1.2	1
88	Survival in young adults diagnosed with follicular lymphoma in a national registry from the Spanish Lymphoma Oncology Group. Annals of Oncology, 2016, 27, vi316.	1.2	0
89	Cost-Utility Analysis of Nivolumab Monotherapy for Metastatic Melanoma Treatment. Value in Health, 2016, 19, A739.	0.3	1
90	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2016, 17, 1248-1260.	10.7	832

#	ARTICLE	IF	CITATIONS
91	GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases. <i>Annals of Oncology</i> , 2016, 27, vi383.	1.2	0
92	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
93	Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel. <i>Breast Care</i> , 2016, 11, 133-138.	1.4	3
94	Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience. <i>Clinical and Translational Oncology</i> , 2016, 18, 1147-1157.	2.4	17
95	Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach. <i>Clinical and Translational Oncology</i> , 2016, 18, 1044-1050.	2.4	0
96	Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. <i>Endocrine-Related Cancer</i> , 2016, 23, R71-R84.	3.1	43
97	Sam68 Mediates the Activation of Insulin and Leptin Signalling in Breast Cancer Cells. <i>PLoS ONE</i> , 2016, 11, e0158218.	2.5	13
98	3211 Follicular lymphoma and clinical characteristics of histologic transformation. <i>European Journal of Cancer</i> , 2015, 51, S652-S653.	2.8	0
99	3201 Survival analysis of follicular lymphoma in a national registry from the spanish oncology lymphoma group. <i>European Journal of Cancer</i> , 2015, 51, S649.	2.8	0
100	25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study. <i>European Journal of Cancer</i> , 2015, 51, S722-S723.	2.8	7
101	SEOM clinical guidelines for the treatment of follicular non-Hodgkinâ€™s lymphoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 1014-1019.	2.4	8
102	SEOM clinical guidelines for the treatment of Hodgkinâ€™s lymphoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 1005-1013.	2.4	8
103	SEOM clinical guidelines in metastatic breast cancer 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 946-955.	2.4	25
104	coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutationâ€™positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). <i>Journal of Translational Medicine</i> , 2015, 13, O4.	4.4	10
105	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2015, 31, 1129-1137.	1.9	37
106	Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice. <i>Clinical and Translational Oncology</i> , 2015, 17, 862-869.	2.4	3
107	Abstract P6-08-10: Prospective study of the impact of the Prosignaâ„¢ assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study. , 2015, , .		2
108	Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF</i>-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9006-9006.	1.6	39

#	ARTICLE	IF	CITATIONS
109	Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C).. Journal of Clinical Oncology, 2015, 33, 9021-9021.	1.6	3
110	Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study. PLoS ONE, 2015, 10, e0124239.	2.5	8
111	Chemotherapy effectiveness in the treatment of non-medullary well-differentiated thyroid cancer: A systematic review.. Journal of Clinical Oncology, 2015, 33, e17058-e17058.	1.6	0
112	Avoidance of Cancer Cell Destruction by the Immune System. , 2014, , 434-443.		0
113	Pathological Complete Response and Changes Related to T Infiltrating Lymphocytes and Regulatory T Cells in Tissue and Peripheral Blood After Neoadjuvant Chemotherapy in Breast Carcinoma. Annals of Oncology, 2014, 25, iv368.	1.2	0
114	Clinical guideline SEOM: cancer of unknown primary site. Clinical and Translational Oncology, 2014, 16, 1091-1097.	2.4	19
115	Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored. Frontiers in Immunology, 2014, 5, 102.	4.8	35
116	Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma. Therapeutic Advances in Hematology, 2014, 5, 78-90.	2.5	6
117	Combined Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutated Melanoma. New England Journal of Medicine, 2014, 371, 1867-1876.	27.0	1,824
118	Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625. Annals of Oncology, 2014, 25, iv120.	1.2	0
119	New Insights into the Role of the Immune Microenvironment in Breast Carcinoma. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	50
120	Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2013, 31, e11577-e11577.	1.6	2
121	The Prevalence and Nature of Cancer-Related Neuropathic Pain in Out-Patient Services in Spain. Open Pain Journal, 2013, 6, 199-207.	0.4	1
122	Pathologic complete response and changes related to T-infiltrating lymphocytes and regulatory T cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast carcinoma.. Journal of Clinical Oncology, 2013, 31, e22073-e22073.	1.6	0
123	Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications. Clinical and Developmental Immunology, 2012, 2012, 1-24.	3.3	28
124	Consolidation Treatment with Y90-Ibritumomab Tiuxetan after R-Chop Induction in High-Risk Patients with Follicular Lymphoma (FL) (GOTEL-FL1LC): A Multicentric, Prospective Study. Annals of Oncology, 2012, 23, ix351.	1.2	1
125	Numb chin syndrome: A warning sign of aggressive B-cell malignancy. Leukemia Research, 2011, 35, e177-e178.	0.8	2
126	Immune Microenvironment in Colorectal Cancer: A New Hallmark to Change Old Paradigms. Clinical and Developmental Immunology, 2011, 2011, 1-9.	3.3	24

#	ARTICLE	IF	CITATIONS
127	Primary intracranial malignant peripheral nerve sheath tumour responding to chemotherapy. <i>Clinical and Translational Oncology</i> , 2010, 12, 231-233.	2.4	3
128	Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety. <i>Oncologist</i> , 2010, 15, 416-427.	3.7	113
129	Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-17.	3.0	13
130	Role of transforming growth factor β^2 in cancer microenvironment. <i>Clinical and Translational Oncology</i> , 2009, 11, 715-720.	2.4	27
131	Cancer and Immune Response: Old and New Evidence for Future Challenges. <i>Oncologist</i> , 2008, 13, 1246-1254.	3.7	53
132	Severe acute hepatitis in a patient treated with anastrozole. <i>Lancet, The</i> , 2007, 369, 23-24.	13.7	27
133	A multicenter sequential phase IV study of oxaliplatin (Oxa) and capecitabine (Cap) followed by irinotecan (Iri) and capecitabine in first line advanced colorectal cancer (ACC). Preliminary results. <i>Journal of Clinical Oncology</i> , 2004, 22, 3652-3652.	1.6	0
134	Hodgkin's Lymphoma: From Tumor Microenvironment to Immunotherapeutic Approach - Body's Own Power Protection Challenges. , 0, , .		0